Mitchell Abrahamsen

Mitchell Abrahamsen, PhD, is an accomplished C-Level executive with extensive experience in the biotechnology and pet nutrition sectors. They served as the Executive Vice President and Chief Commercial Officer at Recombinetics, Inc. from 2017 to 2019 and held senior leadership roles at Hill's Pet Nutrition and Cobb-Vantress/Tyson Foods. Currently, Mitchell is the CEO and Co-Founder of Xena Therapies and a Board Member at Enova Illumination and NovoBind. Additionally, they have held academic positions, including Professor at the University of Minnesota, and are pursuing further education at the University of Washington while holding a Bachelor of Science degree in Biochemistry from the University of Minnesota-Twin Cities.